Patricia LoRusso

Immunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Papers

Driven by 29 papers — median percentile 0. Top paper: “Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study”.

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00584-2

N/A

3.3DataRank · unranked

131 citations

Laura Q M Chow, Justin F Gainor, Patricia LoRusso, Keun-Wook Lee, Hyun Cheol Chung +14 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256

N/A

2.0DataRank · unranked

98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.02.008

N/A

0.759DataRank · unranked

157 citations

Ofir Cohen, Bose Kochupurakkal, D. Kim, Connor E. Dunn, Jorge Buendia +20 more

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

Nature Cancer(2024)10.1038/s43018-024-00729-w

N/A

0.587DataRank · unranked

49 citations

Won Jin Ho, Ludmila Danilova, Joseph A. Tandurella, James M. Leatherman, Christine I. Rafie +22 more

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.111

N/A

0.559DataRank · unranked

6 citations

Rana R. McKay, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman +14 more

Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-5017

N/A

0.538DataRank · unranked

35 citations

Christine I. Rafie, Chenguang Wang, David Lim, Adam Brufsky, Patricia LoRusso +16 more

NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3012

N/A

0.396DataRank · unranked

13 citations

Karen Kelly, Saiama N. Waqar, Elizabeth J. Davis, Geoffrey I. Shapiro, Patricia LoRusso +7 more

SARS-CoV-2 vaccination and phase 1 cancer clinical trials

The Lancet Oncology(2021)10.1016/s1470-2045(21)00017-6

N/A

0.385DataRank · unranked

12 citations

Lillian L. Siu, Emiliano Calvo, Martijn P. Lolkema, Patricia LoRusso, Jean‐Charles Soria +5 more

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9065

N/A

0.360DataRank · unranked

10 citations

Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato, Primo N. Lara +12 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102

N/A

0.360DataRank · unranked

10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0045

N/A

0.359DataRank · unranked

7 citations

Janie Y. Zhang, Wei Wei, Jeffrey Sklar, Jill Lacy, Minghao Zhong +11 more

Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1077

N/A

0.312DataRank · unranked

7 citations

Hatem Soliman, Siqing Fu, Karen A. Gelmon, Albiruni Ryan Abdul Razak, Pamela N. Münster +11 more

A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1799

N/A

0.292DataRank · unranked

6 citations

Gary M. Clark, Charles A. Coltman, Mary L. Disis, S. Gail Eckhardt, Lee M. Ellis +21 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1918

N/A

0.241DataRank · unranked

4 citations

Gabriela Patilea-Vrana, Anthony Sireci, Alexia Iasonos, Brad A. Davidson, Jiang Liu +4 more

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3104

N/A

0.208DataRank · unranked

3 citations

W. Kimryn Rathmell, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A. Trikalinos +9 more

First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4141

N/A

0.108DataRank · unranked

1 citations

Dana B. Cardin, F. Stephen Hodi, Patricia LoRusso, Taha Merghoub, Roberta Zappasodi +8 more

Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3035

N/A

0.104DataRank · unranked

1 citations

Azeet Narayan, J. M. Wolfe, Dennis Vu, Trinh Thi, Chaitanya Kantak +6 more

Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors

JCO Precision Oncology(2024)10.1200/po.23.00289

N/A

0.104DataRank · unranked

1 citations

Azeet Narayan, Yunshan Xu, J. M. Wolfe, Dennis Vu, Thi Trinh +8 more

Analysis of fragment ends in plasma DNA from patients with cancer

medRxiv(2021)10.1101/2021.04.23.21255935

N/A

0DataRank · unranked

9 citations

Bradon R. McDonald, Michelle D. Stephens, Tania Contente‐Cuomo, Havell Markus, Maria Farooq +17 more

A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial

Heliyon(2023)10.1016/j.heliyon.2023.e18680

N/A

0DataRank · unranked

5 citations

Alex P. Toscano, Mohammadhadi Bagheri, Jeffrey Solomon, Laura B. Machado, Patricia LoRusso +4 more

Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.431

N/A

0DataRank · unranked

10 citations

Matthew I. Milowsky, Noah M. Hahn, David J. Kwiatkowski, Alicia K. Morgans, Nancy B. Davis +10 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

1033TiP A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1417

N/A

0DataRank · unranked

4 citations

Timothy A. Yap, Sarina A. Piha‐Paul, Patricia LoRusso, Siwen Hu‐Lieskovan, Christopher J. Shepherd +6 more

Improved methods for RNAseq-based alternative splicing analysis

Scientific Reports(2021)10.1038/s41598-021-89938-2

N/A

0DataRank · unranked

44 citations

Apurva M. Hegde, Jessica D. Lang, Elizabeth A. Raupach, Vinodh Narayanan, Matt Huentelman +13 more

High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-011653

N/A

0DataRank · unranked

1 citations

Barani Kumar Rajendran, Shruti Desai, Joanna Gibson, Jassim DiPalermo, Patricia LoRusso +5 more

FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0098

N/A

0DataRank · unranked

1 citations

Cong Chen, Jin Y. Jin, Scott Van Wart, Sarah K. Martin, Brad A. Davidson +4 more

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.8563

N/A

0DataRank · unranked

0 citations

Marc R. Radke, Navid Hafez, Hatem Soliman, Siqing Fu, Shumei Kato +11 more

Bisbee: A proteomics validated analysis package for detecting differential splicing, identifying splice outliers, and predicting splice event protein effects

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.08.13.250167

N/A

0DataRank · unranked

0 citations

Apurva M. Hegde, Jessica D. Lang, Elizabeth A. Raupach, Christophe Legendre, Winnie S. Liang +8 more

Genome-wide analysis of aberrant position and sequence of plasma DNA fragment ends in patients with cancer

Science Translational Medicine(2023)10.1126/scitranslmed.abm6863

N/A

0DataRank · unranked

59 citations

Bradon R. McDonald, Michelle D. Stephens, Tania Contente‐Cuomo, Havell Markus, Maria Farooq +17 more

Patricia LoRusso

Indexed papers

Top data-sharing exemplar

Papers